Pulmonary Hypertension Associated with Severe Interstitial Pneumonia Successfully Treated with Inhaled Treprostinil: A Case Report
Inhaled treprostinil is the first-choice drug for the treatment of Group 3 pulmonary hypertension (PH) associated with chronic lung disease. A 72-year-old man was diagnosed with interstitial pneumonia, and his respiratory symptoms had gradually worsened. Echocardiography revealed a maximum tricuspid regurgitation pressure gradient (TRPG) of 64 mmHg, and the patient was diagnosed with group 3 PH. Subsequently, he was admitted to the hospital with acute heart failure. Inhaled treprostinil was prescribed, his B-type natriuretic peptide level and maximum TRPG subsequently improved, and his oxygen requirement decreased. Treprostinil inhalation may be effective in treating patients with severe respiratory symptoms of interstitial pneumonia.
Authors
- Tomoya Tateishi (ORCID: https://orcid.org/0000-0001-5402-3185)
- Yasunari Miyazaki (ORCID: https://orcid.org/0000-0002-9073-9815)
- Shiro Sonoda
- Takayuki Yamada (ORCID: https://orcid.org/0000-0002-5349-6690)
- Haruhiko Furusawa (ORCID: https://orcid.org/0000-0002-5569-1051)
- Masaya Otsuka
- Tsuyoshi Shirai (ORCID: https://orcid.org/0000-0002-6295-3494)
- Atsushi Sawada (ORCID: https://orcid.org/0000-0002-6005-8736)
- Takashi Yasuda
- S. Aoki
Institutions
- Sleep Research Society (US)
- Tokyo Institute of Psychiatry (JP)
Publication Details
- Journal
- Internal Medicine
- Published
- 2025-01-01
- DOI
- https://doi.org/10.2169/internalmedicine.6206-25
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00